Roche has reported a 7% increase in full-year 2024 sales at constant exchange rates (CER), reaching CHF 60.5bn ($66.9bn). The ...

Q4 earnings for companies such as Johnson & Johnson, Teva, and Roche highlight the impact of significant innovations brought ...

Here’s the latest on symptoms, treatments and testing. By Dani Blum Dani Blum has reported on Covid since the spring of 2020. There are few constants when it comes to Covid, but one thing has ...

Reports of rising cases of a flu-like illness in China, where COVID-19 was first detected five years ago, sparked international concerns about the potential for another worldwide pandemic.

Covid-19 is now ubiquitous – but hospitalisations seem to be on a downward trajectory. No one knows why. When virologists took their first peek at XEC, the Covid-19 variant which started to ...

The Occupational Safety and Health Administration Jan. 13 announced that it terminated efforts to establish a final COVID-19 safety standard to protect workers in health care settings. The agency said ...

It’s been five years since the COVID-19 pandemic began—and a lot has changed. From early in the pandemic until now, COVID went from causing fear, death, shortages, and uncertainty to being regarded by ...

Tecfidera has interactions with some other drugs. Examples include ocrelizumab (Ocrevus) and alemtuzumab (Lemtrada). Tecfidera is prescribed for the following conditions in adults: clinically ...

Real-world discontinuation rates of ocrelizumab are low, similar to pivotal trials, with rates between 3.2% and 4.1% for RRMS and PPMS. Side effects are the most common reason for discontinuation ...

Subcutaneous ocrelizumab (SC OCR) maintains a safety profile similar to intravenous administration in multiple sclerosis patients. A 920 mg SC OCR dose was identified as optimal, with mild to ...